EVITA: a tool for the early EValuation of pharmaceutical Innovations with regard to Therapeutic Advantage

BACKGROUND: New drugs are generally claimed to represent a therapeutic innovation. However, scientific evidence of a substantial clinical advantage is often lacking. This may be the result of using inadequate control groups or surrogate outcomes only in the clinical trials. In view of this, EVITA wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Püntmann, Isabel, Schmacke, Norbert, Melander, Arne, Lindberg, Gunnar, Mühlbauer, Bernd
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2858124/
https://www.ncbi.nlm.nih.gov/pubmed/20233429
http://dx.doi.org/10.1186/1472-6904-10-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2858124/
https://www.ncbi.nlm.nih.gov/pubmed/20233429
http://dx.doi.org/10.1186/1472-6904-10-5

Ejemplares similares